|
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial
Circulation. 2005 Jun; 111(25):3366-73. Epub 2005 Jun 20
Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E; JUMBO-TIMI 26 Investigators. |
|
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Am J Cardiol. 2005 Jun; 95(11):1295-301.
Madan M, Radhakrishnan S, Reis M, Paradiso-Hardy FL, Godin-Edgecombe M, Sparling C, Phillips AM, Shanmugasegaram S, Fort S, Naqvi SZ, Cohen EA. |
|
Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke trea
Stroke. 2005 Jun; 36(6):1160-5. Epub 2005 May 12
Eckert B, Koch C, Thomalla G, Kucinski T, Grzyska U, Roether J, Alfke K, Jansen O, Zeumer H. |
|
Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. British Women´s Heart and Health Study
Thromb Haemost. 2005 May; 93(5):955-63.
Lawlor DA, Smith GD, Rumley A, Lowe GD, Ebrahim S |
|
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial
Circulation. 2005 Mar; 111(11):1390-7.
Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S; ASPIRE Investigators |
|
Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implemen
J Am Coll Cardiol. 2005 Mar; 45(6):832-7.
Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX Jr, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LK; CRUSADE Investigators |
|
Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Im
Circulation. 2005 Mar; 111(10):1225-32.
Sonel AF, Good CB, Mulgund J, Roe MT, Gibler WB, Smith SC Jr, Cohen MG, Pollack CV Jr, Ohman EM, Peterson ED; CRUSADE Investigators |
|
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women´s Health Initiative Observational Study.
Arch Intern Med. 2005 Mar; 165(5):500-8.
Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH Jr, Howard BV, Assaf AR, Prentice R; Women´s Health Initiative Research Group |
|
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study
Circulation. 2005 Mar; 111(9):1153-9. Epub 2005 Feb 28
Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US |
|
Management of non-ST-segment-elevation acute coronary syndromes in Spain. The DESCARTES (Descripcion del Estado de los Sindromes Coronarios Agudos en un Registro Temporal ESpanol) study
Rev Esp Cardiol. 2005 Mar; 58(3):244-52.
Bueno H, Bardaji A, Fernandez-Ortiz A, Marrugat J, Marti H, Heras M; Investigadores del Estudio DESCARTES. |
|
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)
J Thromb Haemost. 2005 Mar; 3(3):459-64.
Vossen CY, Conard J, Fontcuberta J, Makris M, VAN DER Meer FJ, Pabinger I, Palareti G, Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR |
|
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)
Am J Cardiol. 2005 Mar; 95(5):581-5.
Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ; REPLACE-2 Investigators |
|
The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study
Blood. 2005 Ene; 105(2):862-4. Epub 2004 Sep 14
Sensebe L, Giraudeau B, Bardiaux L, Deconinck E, Schmidt A, Bidet ML, Leniger C, Hardy E, Babault C, Senecal D |
|
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients
Thromb Haemost. 2005 Ene; 93(1):76-9.
Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group |
|
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Scand Cardiovasc J. 2004 Dic; 38(6):353-6.
Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. |
|
Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials
Am Heart J. 2004 Dic; 148(6):990-7.
Schleinitz MD, Olkin I, HeidenreichPA |
|
Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study
Circulation. 2004 Nov; 104(10):3046-51. Epub 2004 Jun 29
Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, Nordestgaard BG |
|
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies
Arch Intern Med. 2004 Oct; 164(19):2106-10.
Hirsh J, Bhatt DL |
|
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Fox
Circulation. 2004 Sep; 110(10):1202-8. Epub 2004 Ago 16
Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial |
|
Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment-Elevation Myocardial Infarction. An INTEGRITI (Integrilin and Tenectep
Circulation. 2004 Ago; 110(6):679-84. Epub 2004 Jul 19
Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA, Cholera S, Krishnan R, Califf RM, Braunwald E |
